Pfizer Inc. (NYSE:PFE) Shares Bought by AssuredPartners Investment Advisors LLC

AssuredPartners Investment Advisors LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 49.6% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 60,969 shares of the biopharmaceutical company’s stock after purchasing an additional 20,210 shares during the period. AssuredPartners Investment Advisors LLC’s holdings in Pfizer were worth $1,545,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at about $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC grew its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer during the 4th quarter valued at about $30,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Trading Up 0.3%

Shares of Pfizer stock opened at $24.04 on Tuesday. The stock has a market cap of $136.68 billion, a P/E ratio of 17.42, a P/E/G ratio of 0.87 and a beta of 0.57. The stock’s 50 day simple moving average is $23.30 and its 200-day simple moving average is $24.88. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.82 EPS. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.15%. The ex-dividend date was Friday, May 9th. Pfizer’s dividend payout ratio is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.